Adverse Events Associated With Antibody-Drug Conjugates Across Cancer Types
Researchers say they have identified adverse events that are more likely to occur in cancer patients receiving antibody-drug conjugates.
Researchers say they have identified adverse events that are more likely to occur in cancer patients receiving antibody-drug conjugates.
Higher exposure to PFAS, phenols, and parabens is associated with previous cancer diagnosis in women but not men, a study suggests.
Adding HIPEC to interval cytoreductive surgery improves long-term outcomes in stage III epithelial ovarian cancer, a phase 3 trial suggests.
Adding atezolizumab to bevacizumab and platinum-based chemotherapy did not improve PFS in recurrent, platinum-sensitive ovarian cancer.
A genetic testing station can increase uptake and improve the efficiency of genetic testing for patients with ovarian cancer, a study suggests.
Patients from racial and ethnic minority groups are still underrepresented in cancer research, despite efforts to make clinical trials more diverse.
Screening can lead to earlier diagnosis of high-grade serous ovarian cancer, but this does not translate to a substantial improvement in survival, according to researchers.
Cancer patients with ICI-induced acute pancreatitis may require abdominal imaging for diagnosis and monitoring for exocrine pancreatic insufficiency.
Pharmaceutical experts review ocular adverse effects related to antibody-drug conjugates.
Researchers found a lower incidence of cancer and a lower risk of cancer death among women who underwent bariatric surgery.